Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iodine-131, and Lutetium-177 directed at multiple validated cancer targets, including CD45, CD33, CD38, CD47, HER2, and HER3 for targeted conditioning prior to cell and gene therapies, such as bone marrow transplant and cancer therapeutics as single agents or in combination with other therapeutic modalities. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 immunotherapy targeted radiotherapy; and AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors. The company was incorporated in 2000 and is based in New York, New York.

Actinium Pharmaceuticals, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

NEW YORK, AUG. 14, 2026 /PRNEWSWIRE/ -- ACTINIUM PHARMACEUTICALS, INC.(NYSE AMERICAN: ATNM) (ACTINIUM OR THE COMPANY), A PIONEER IN THE DEVELOPMENT OF TARGETED RADIOTHERAPIES, TODAY ANNOUNCED ADVANCES ACROSS ITS ACTIMAB-A PROGRAM, INCLUDING RECENTLY ACQUIRED PATENTS ADDING TO A BROAD SUITE OF IP, AND EXPANSION OF THE COMPANY'S MANUFACTURING CAPACITY, AS THE PROGRAM APPROACHES CLINICAL MILESTONES FROM THE FOURTH QUARTER OF 2026 AND INTO 2027. THE COMPANY ALSO PROVIDED AN UPDATE ON THE STATUS OF ITS NYSE AMERICAN LISTING.

ACTINIUM PHARMACEUTICALS ANNOUNCES ACTIMAB-A INTELLECTUAL PROPERTY AND MANUFACTURING ADVANCES AND PROVIDES NYSE AMERICAN LISTING UPDATE

NEW KRAS-MUTANT DATA SHOW ATNM-400 OUTPERFORMED STANDARD-OF-CARE INHIBITORS SOTORASIB AND ADAGRASIB AS A MONOTHERAPY. TREATMENT WITH THESE AGENTS INCREASED EXPRESSION OF THE ATNM-400 TARGET GREATER THAN 3.5X AND ENHANCED THEIR EFFECT IN COMBINATION ADDITIONAL DATA IN THE EGFR-MUTANT SETTING DEMONSTRATED POWERFUL SYNERGY WITH OSIMERTINIB DUE TO ENHANCED TARGET EXPRESSION IN TREATED ANIMALS RESULTING IN COMPLETE TUMOR REGRESSION IN THE COMBINATION ARM THE DATA WITH EGFR AND KRAS MUTATIONS WHICH ACCOUNT FOR APPROXIMATELY 40-50 PERCENT OF ALL NSCLC CASES PROVIDE COMPELLING EVIDENCE OF THE POTENTIAL OF ATNM-400 AS A MONOTHERAPY OR IN COMBINATION WITH INHIBITORY AGENTS AGAINST THESE MUTATIONS ATNM-400 IS A RADIOCONJGATE COMPRISING AN ANTIBODY COUPLED TO ACTINIUM-225 WHICH CAUSES CELL DEATH VIA DOUBLE STRANDED DNA BREAKS INDEPENDENT OF CELLULAR MECHANISMS AND OFFERS BROAD POTENTIAL AS A MUTATION AGNOSTIC AGENT IN NSCLC WHERE ITS TARGET IS EXPRESSED IN OVER 90 PERCENT OF TUMORS WITH GREATER EXPRESSION AS RESISTANCE EMERGES NEW YORK, JUNE 3, 2026 /PRNEWSWIRE/ -- ACTINIUM PHARMACEUTICALS, INC.(NYSE AMERICAN: ATNM) (ACTINIUM OR THE COMPANY), A PIONEER IN THE DEVELOPMENT OF TARGETED RADIOTHERAPIES, ON JUNE 2, 2026, PRESENTED NEW PRECLINICAL DATA ON ATNM-400 IN NON-SMALL CELL LUNG CANCER (NSCLC) AT THE SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (SNMMI) 2026 ANNUAL MEETING IN LOS ANGELES, CALIFORNIA.

ACTINIUM PRESENTS NEW ATNM-400 DATA IN KRAS AND EGFR MUTANT MODELS AT SNMMI 2026 SUPPORTING A MUTATION-AGNOSTIC OPPORTUNITY IN NON-SMALL CELL LUNG CANCER

NEW DATA DEMONSTRATED ATNM-400 REMAINS POTENTLY ACTIVE IN PROSTATE CANCER CELLS AND TUMORS RESISTANT TO ALL THREE APPROVED ANDROGEN RECEPTOR INHIBITORS (ARPIS) -ENZALUTAMIDE (XTANDI), APALUTAMIDE (ERLEADA), AND DAROLUTAMIDE (NUBEQA)- DIRECTLY TARGETING THE POINT OF FAILURE FOR A HIGH PROPORTION OF MCRPC PATIENTS  ATNM-400 SUBSTANTIALLY OUTPERFORMED APALUTAMIDE AND DAROLUTAMIDE IN AN ARPI-RESISTANT TUMOR MODEL, AND IN COMBINATION WITH EITHER ARPI IT SHOWED DURABLE COMPLETE RESPONSES, SUPPORTING BOTH MONOTHERAPY AND COMBINATION STRATEGIES IN REFRACTORY DISEASE SIMILAR TO PRIOR DATA WITH ENZALUTAMIDE ATNM-400 DELIVERED SUPERIOR TUMOR CONTROL AS A SINGLE BOLUS OR REPEAT DOSE WITH A CONSISTENT SAFETY PROFILE AND MINIMAL OFF-TARGET TOXICITY ACROSS TREATMENT REGIMENS, INDICATING DOSING FLEXIBILITY AND A WIDE THERAPEUTIC WINDOW THAT COULD DE-RISK CLINICAL TRANSLATION. IN HIGHPSMA EXPRESSING DISEASE, ATNM-400 OUTPERFORMED 177LU-PSMA-617 IN TERMS OF ACTIVITY AND WAS SIMILAR TO 225AC-PSMA-617.

ACTINIUM PHARMACEUTICALS ORAL PRESENTATION AT SNMMI 2026 HIGHLIGHTS ATNM-400 OVERCOMING RESISTANCE TO ALL THREE APPROVED ANDROGEN RECEPTOR INHIBITORS AND OFFERS FLEXIBLE, WELL-TOLERATED DOSING IN PROSTATE CANCER MODELS

PROVEN CHIEF MEDICAL OFFICER AT SEVERAL PUBLICLY LISTED AND CLINICAL-STAGE ONCOLOGY COMPANIES WITH SUCCESSFUL TRACK RECORD DEVELOPING MULTIPLE MODALITIES INCLUDING RADIOTHERAPIES FROM PRECLINICAL THROUGH GLOBAL APPROVALS ACROSS HEMATOLOGIC MALIGNANCIES AND SOLID TUMORS PLAYED A LEADING ROLE IN CLINICAL DEVELOPMENT AND WORLDWIDE APPROVALS OF ERBITUX AT MERCK KGAA LEADING TO ITS BLOCKBUSTER STATUS LED CLINICAL DEVELOPMENT AS CMO OF NBE THERAPEUTICS WHICH WAS ACQUIRED BY BOEHRINGER INGELHEIM FOR $1.4 BILLION, AND MOST RECENTLY CMO OF RADIOTHERAPY COMPANY FULL-LIFE TECHNOLOGIES TIMELY KEY HIRE WITH DR. HEEGER'S OPERATIONAL RIGOR AND CLINICAL EXPERTISE EXPECTED TO ELEVATE DEVELOPMENT OF ACTIMAB-A, ATNM-400, AND IOMAB-ACT AS ACTINIUM ADVANCES TOWARD KEY DATA READOUTS AND EXPANDED CLINICAL TRIALS IN 2H:2026 NEW YORK, JUNE 1, 2026 /PRNEWSWIRE/ -- ACTINIUM PHARMACEUTICALS, INC. (NYSE AMERICAN: ATNM) (ACTINIUM OR THE COMPANY), A PIONEER IN THE DEVELOPMENT OF TARGETED RADIOTHERAPIES, TODAY ANNOUNCED THE APPOINTMENT OF STEFFEN HEEGER, MD, MSC, AS CHIEF MEDICAL OFFICER. DR. HEEGER BRINGS A RARE COMBINATION OF RADIOTHERAPY EXPERTISE, GLOBAL ONCOLOGY DRUG DEVELOPMENT LEADERSHIP, AND PUBLIC-COMPANY EXPERIENCE.

ACTINIUM APPOINTS ACCOMPLISHED ONCOLOGY EXPERT STEFFEN HEEGER MD, MSC AS CHIEF MEDICAL OFFICER TO DRIVE REJUVENATED PIPELINE DEVELOPMENT

OPTIMIZATION OF CHELATOR-TO-ANTIBODY RATIO (CAR) IS A KEY DESIGN PARAMETER FOR NEXT-GENERATION RADIOCONJUGATES, PRESENTING TUNABLE LEVERS ACTINIUM IS UTILIZING TO ENGINEER MORE EFFECTIVE DRUG CANDIDATES OPTIMIZED CAR IMPROVED TUMOR TARGETING, INTERNALIZATION, AND PHARMACOKINETICS OF 225AC-LABELED ANTIBODIES LOWER-CAR CONJUGATES PRESERVED TUMOR TARGETING WHILE REDUCING OFF-TARGET LIVER AND SPLEEN UPTAKE, SUPPORTING A WIDER THERAPEUTIC WINDOW THAT MAY ENABLE HIGHER, SAFER DOSING FINDINGS REINFORCE ACTINIUM'S PROPRIETARY RADIOCHEMISTRY EXPERTISE AND DIRECTLY SUPPORT THE COMPANY'S BROADER RADIOCONJUGATE PIPELINE A CAPABILITY THAT APPLIES TO EVERY PROGRAM FROM THE PLATFORM NEW YORK, JUNE 1, 2026 /PRNEWSWIRE/ -- ACTINIUM PHARMACEUTICALS, INC.(NYSE AMERICAN: ATNM) (ACTINIUM OR THE COMPANY), A PIONEER IN THE DEVELOPMENT OF TARGETED RADIOTHERAPIES, ON MAY 31, 2026 PRESENTED NEW RADIOCHEMISTRY DATA AT THE SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (SNMMI) 2026 ANNUAL MEETING TAKING PLACE IN LOS ANGELES, CALIFORNIA. THE POSTER PRESENTED A SYSTEMATIC EVALUATION OF CHELATOR-TO-ANTIBODY RATIO (CAR) OPTIMIZATION FOR ACTINIUM-225 (225AC)-LABELED ANTIBODY RADIOCONJUGATES, A CRITICAL BUT OFTEN UNDERAPPRECIATED DESIGN PARAMETER THAT DIRECTLY INFLUENCES RADIOLABELING EFFICIENCY, ANTIGEN BINDING, INTERNALIZATION, AND BIODISTRIBUTION.

ACTINIUM PHARMACEUTICALS PRESENTS NEW RADIOCHEMISTRY DATA AT SNMMI 2026 DEMONSTRATING THAT CAR OPTIMIZATION IMPROVES TUMOR TARGETING AND PHARMACOKINETICS OF ACTINIUM-225 RADIOCONJUGATES

TOGETHER THE ALLOWANCES DEEPEN PROTECTION ACROSS TWO PRIORITY FRANCHISES AND REINFORCE A PATENT ESTATE OF APPROXIMATELY 250 ISSUED AND PENDING PATENTS AND PATENT APPLICATIONS WORLDWIDE NEW YORK, MAY 29, 2026 /PRNEWSWIRE/ -- ACTINIUM PHARMACEUTICALS, INC. (NYSE AMERICAN: ATNM) (ACTINIUM OR THE COMPANY), A LEADER IN THE DEVELOPMENT OF TARGETED RADIOTHERAPIES, TODAY ANNOUNCED THAT THE CANADIAN INTELLECTUAL PROPERTY OFFICE (CIPO) HAS ISSUED NOTICES OF ALLOWANCE FOR TWO PATENT APPLICATIONS SPANNING THE COMPANY'S ACTIMAB-A AND IOMAB-ACT PROGRAMS. THE ALLOWANCES BROADEN ACTINIUM'S INTELLECTUAL PROPERTY PROTECTION ACROSS BOTH HEMATOLOGIC MALIGNANCIES AND NEXT-GENERATION CONDITIONING FOR GENE-EDITED CELL-BASED THERAPIES IN CANADA, AN IMPORTANT MARKET WITHIN THE COMPANY'S GROWING GLOBAL PATENT ESTATE.

ACTINIUM PHARMACEUTICALS RECEIVES TWO PATENT ALLOWANCES SPANNING ITS ACTIMAB-A AND IOMAB-ACT PROGRAMS

NEW YORK, MAY 29, 2026 /PRNEWSWIRE/ -- ACTINIUM PHARMACEUTICALS, INC. (NYSE AMERICAN: ATNM) (ACTINIUM OR THE COMPANY), A LEADER IN THE DEVELOPMENT OF TARGETED RADIOTHERAPIES, TODAY ANNOUNCED IT WILL PROVIDE A PROGRAM UPDATE ON ITS FIRST-IN-CLASS ACTINIUM-225 (225AC) ANTIBODY RADIOCONJUGATE, ATNM-400, HIGHLIGHTING NEW DATA THAT WILL BE SHOWCASED ACROSS THREE PRESENTATIONS AT THE SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (SNMMI) 2026 ANNUAL MEETING, TAKING PLACE MAY 30-JUNE 2, 2026, IN LOS ANGELES, CALIFORNIA. TWO OF THE PRESENTATIONS SHOWCASE ATNM-400'S DIFFERENTIATED PROFILE ACROSS PROSTATE CANCER AND NON-SMALL CELL LUNG CANCER (NSCLC), WHILE A THIRD DEMONSTRATES THE IMPORTANCE OF RADIOCONJUGATE OPTIMIZATION FOR RADIOTHERAPIES IN THE CONTEXT OF THE COMPANY'S PIPELINE CANDIDATES.

ACTINIUM PHARMACEUTICALS TO PRESENT ATNM-400 PROGRAM UPDATE AT SNMMI 2026 CONFERENCE ON MAY 31-JUNE 2 AND PROVIDES NYSE AMERICAN LISTING STANDARDS NOTICE

BURLINGTON, MASS. & BELOIT, WIS.--(BUSINESS WIRE)--PARTNERSHIP COMBINES NORTHSTAR'S COMMERCIAL-SCALE RADIOISOTOPE PRODUCTION CAPABILITIES WITH QSA GLOBAL'S EXPERTISE IN MANAGEMENT OF RADIUM-226.

NORTHSTAR AND QSA GLOBAL ANNOUNCE MULTI-YEAR STRATEGIC PARTNERSHIP TO STRENGTHEN ACTINIUM-225 SUPPLY CHAIN FOR TARGETED ALPHA THERAPIES

 ATNM-400 IN NSCLC: NEW DATA DEMONSTRATES ATNM-400'S POTENTIAL IN KRAS-MUTATEDMODELS SUPPORTING ITS DEVELOPMENT AS A MUTATION-AGNOSTIC THERAPY IN SETTINGS WHERERESISTANCE TO EGFR- AND KRAS-TARGETED AGENTS REMAINS A MAJOR CLINICAL CHALLENGE  ATNM-400 IN PROSTATE CANCER: NEW DATA FURTHER SUPPORTS ATNM-400 AS A POTENTIALTREATMENT OPTION ACROSS THE SPECTRUM OF PSMA-HIGH, PSMA-LOW, AND PSMA-NEGATIVEDISEASE, ADDRESSING A KEY LIMITATION OF PSMA-TARGETED THERAPIES  RADIOCONJUGATION PLATFORM: NEW DATA DEMONSTRATES THAT OPTIMIZING CHELATOR-TO-ANTIBODY RATIO(CAR) IMPROVES TUMOR TARGETING, INTERNALIZATION, AND PHARMACOKINETICS OF 225AC-LABELEDANTIBODIES, DIRECTLY SUPPORTING ATNM-400 DEVELOPMENT AND REINFORCING A PROPRIETARYRADIOCHEMISTRY CAPABILITY THAT UNDERPINS ACTINIUM'S BROADER PIPELINE NEW YORK, MAY 6, 2026 /PRNEWSWIRE/ --ACTINIUM PHARMACEUTICALS, INC. (NYSE AMERICAN: ATNM) (ACTINIUM OR THE COMPANY), A PIONEER IN THE DEVELOPMENT OF TARGETED RADIOTHERAPIES, TODAY ANNOUNCED THE UPCOMING PRESENTATION OF THREE ABSTRACTS AT THE SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (SNMMI) 2026 ANNUAL MEETING, TAKING PLACE MAY 30-JUNE 2, 2026, IN LOS ANGELES, CALIFORNIA. THE PRESENTATIONS INCLUDE TWO POSTERS ON ATNM-400, ACTINIUM'S FIRST-IN-CLASS ACTINIUM-225 (225AC) ANTIBODY RADIOCONJUGATE, DEMONSTRATING ITS POTENTIAL IN PROSTATE CANCER AND NON-SMALL CELL LUNG CANCER (NSCLC), AS WELL AS A THIRD POSTER PRESENTING PRECLINICAL RADIOCHEMISTRY DATA ON CHELATOR-TO-ANTIBODY RATIO (CAR) OPTIMIZATION THAT UNDERPINS ATNM-400 DEVELOPMENT.

ACTINIUM PHARMACEUTICALS ANNOUNCES THREE SNMMI 2026 PRESENTATIONS HIGHLIGHTING DIFFERENTIATED PROFILE OF ATNM-400 ACROSS LUNG AND PROSTATE CANCER AND RADIOCONJUGATE OPTIMIZATION

ATNM-400 DEMONSTRATES PAN-TUMOR ACTIVITY ACROSS PROSTATE, LUNG, AND BREAST CANCER MODELS, SUPPORTING MULTI-INDICATION DEVELOPMENT POTENTIAL IN PROSTATE CANCER, ATNM-400 DEMONSTRATES EFFICACY ACROSS BOTH HIGH PSMA-EXPRESSING AND, IMPORTANTLY, LOW PSMA-EXPRESSING PROSTATE CANCER MODELS, UNLIKE MANY PSMA-TARGETED RADIOLIGAND THERAPIES THAT WORK ONLY IN PSMA-HIGH SETTINGS IN EGFR-MUTANT NON-SMALL CELL LUNG CANCER, ATNM-400 DEMONSTRATES GREATER TUMOR GROWTH INHIBITION THAN OSIMERTINIB (A TYROSINE KINASE INHIBITOR) PLUS CHEMOTHERAPY AND OUTPERFORMS THE APPROVED TROP-2 ADC DATO-DXD (DATROWAY), THE EGFR-CMET BISPECIFIC ANTIBODY AMIVANTAMAB (RYBREVANT) AND THE EXPERIMENTAL EGFR-HER3 ADC IZALONTAMAB BRENGITECAN, SUPPORTING POTENTIAL USE ACROSS FIRST-, SECOND-, AND THIRD-LINE TREATMENT SETTINGS IN BREAST CANCER, NEW HEAD-TO-HEAD DATA SHOWS ATNM-400 ACHIEVES EFFICACY COMPARABLE TO THE APPROVED HER2-ADC TRASTUZUMAB DERUXTECAN (ENHERTU) IN TRASTUZUMAB-RESISTANT MODELS, WITH DURABLE TUMOR CONTROL OBSERVED AFTER TREATMENT DISCONTINUATION - EXTENDING THE COMPANY'S PRIOR SABCS 2025 DATA AND SUPPORTING POTENTIAL FOR LESS FREQUENT DOSING OF ATNM-400 COMPARED TO ADCS ATNM-400 IS WELL TOLERATED, WITH NO IN VIVO TOXICITIES OBSERVED AT EFFICACIOUS DOSES, PROVIDING A FAVORABLE THERAPEUTIC INDEX THAT SUPPORTS MONOTHERAPY AND COMBINATION DEVELOPMENT NEW YORK, APRIL 22, 2026 /PRNEWSWIRE/ -- ACTINIUM PHARMACEUTICALS, INC. (NYSE AMERICAN: ATNM) (ACTINIUM OR THE COMPANY), A PIONEER IN THE DEVELOPMENT OF TARGETED RADIOTHERAPIES, TODAY ANNOUNCED PRECLINICAL RESULTS FOR ATNM-400 ACROSS PROSTATE, LUNG, AND BREAST CANCER MODELS PRESENTED AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) ANNUAL MEETING IN SAN DIEGO, CA. ATNM-400 IS A NOVEL, FIRST-IN-CLASS TARGETED RADIOTHERAPY UTILIZING THE ACTINIUM-225 (AC-225) RADIOISOTOPE THAT TARGETS A NON-PSMA MEMBRANE ANTIGEN OVEREXPRESSED IN ADVANCED AND THERAPY-REFRACTORY SOLID TUMORS ACROSS MULTIPLE ONCOLOGY INDICATIONS.

ACTINIUM PHARMACEUTICALS, INC. ANNOUNCES COMPELLING PAN-TUMOR DATA FOR ATNM-400 DEMONSTRATING BROAD EFFICACY ACROSS PROSTATE, LUNG, AND BREAST CANCER MODELS AT THE 2026 AMERICAN ASSOCIATION OF CANCER RESEARCH ANNUAL MEETING

Actinium Pharmaceuticals, Inc.

ATNM

Price

Financial Reports

No items found.

Press Releases

Actinium Pharmaceuticals, Inc.

ATNM.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

ATNM